SHAIL RAKESH MODI, TERRICK ANDEY^*

Oncology Research, Vol.32, No.11, pp. 1709-1721, 2024, DOI:10.32604/or.2024.053972 - 16 October 2024

Abstract Objectives: EGFR tyrosine kinase inhibitor (EGFR-TKI) therapies such as erlotinib and gefitinib are approved for the treatment of non-small cell lung cancer (NSCLC). However, the high incidence of acquired resistance to these EGFR-TKIs may preclude their effectiveness. Piperlongumine (PPL), an extract from the long pepper fruit (Piper longum), has been shown to possess anticancer properties. The purpose of the study was to investigate piperlongumine as an anticancer agent and to study a combination treatment approach with EGFR-TKIs against lung cancer cells. Methods: Anticancer efficacy of PPL, erlotinib (ERL), gefitinib (GEF), and cisplatin (CIS) were investigated in… More >

Li Xu, Kang Li, Jia Li, Liyu Liu, Fang Xu, Yan Xu, Yi Kong, Xingxiang Pu, Qianzhi Wang, Jingyi Wang, Bolin Chen^*, Lin Wu^*

Oncologie, Vol.24, No.3, pp. 579-590, 2022, DOI:10.32604/oncologie.2022.022121 - 19 September 2022

Abstract Background: Non-small cell lung cancer (NSCLC), caused by abnormal gene drive, may have primary drug resistance after treatment with tyrosine kinase inhibitors (EGFR-TKIs). Therefore, we explore whether the primary drug-resistant NSCLC treated with EGFR-TKI is related to the miR-21/Sonic Hedgehog (SHH)/PI3K/AKT pathway. Methods: The patients from our hospital who meet the AJCC TNM staging (7th edition) stage IIIB and stage IV NSCLC were selected in this case study. Thereafter, the treatment response of EGFR-TKIs was evaluated according to the solid tumor efficacy evaluation standard (version 1.1). The patients were divided into the EGFR-TKIs primary drug resistance group… More >

Yudie Yang^*1, Xia Zhang^†1, Yajie Gao^*, Yan Dong^*, Di Wang^*, Yanping Huang^*, Tianhao Qu^*, Buqun Fan^*, Qizheng Li^*, Chunxia Zhang^*, Xiaonan Cui^*, Bin Zhang^*

Oncology Research, Vol.29, No.1, pp. 63-74, 2021, DOI:10.3727/096504022X16462176651719

Abstract Lung cancer is a malignant tumor with high incidence and mortality across the world. The use of immune checkpoint inhibitors for lung cancer has improved the prognosis of some lung cancer patients to a greater extent and provided a new direction for the clinical treatment of lung cancer. Immunotherapy still has limitations in terms of its appropriate population and adverse reactions. Particularly for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation, there has been no major breakthrough in current immunotherapy. Whether immunotherapy can bring new benefits after drug resistance is More >

Chunya Hu, Yu He^*

Oncologie, Vol.23, No.2, pp. 241-250, 2021, DOI:10.32604/Oncologie.2021.015828 - 22 June 2021

Abstract Objective: The aim of the present study was to investigate the anti-tumor effects of formononetin on human nonsmall cell lung cancer (NSCLC) and its potential molecular mechanism. Methods: A549 cells were treated with different concentrations of formononetin, then detected the cell proliferation, apoptosis and the expression of HIPK2 respectively by MTT assay, flow cytometry analysis and RT-qPCR. Then the interaction between miR- 27a-3p and its target gene HIPK2 was verified through luciferase reporter assay. The expression of miR-27a- 3p, HIPK2, and p53 was detected after being treated with different formononetin concentrations by RT-qPCR and western blot. Results: More >

Nahathai Dukaew^*†, Teruaki Konishi^‡§, Kongthawat Chairatvit^¶, Narongchai Autsavapromporn^#, Noppamas Soonthornchareonnon^**, Ariyaphong Wongnoppavich^†

Oncology Research, Vol.28, No.2, pp. 161-175, 2020, DOI:10.3727/096504019X15736439848765

Abstract Radiotherapy (RT) is an important treatment for non-small cell lung cancer (NSCLC). However, the major obstacles to successful RT include the low radiosensitivity of cancer cells and the restricted radiation dose, which is given without damaging normal tissues. Therefore, the sensitizer that increases RT efficacy without dose escalation will be beneficial for NSCLC treatment. Eurycomalactone (ECL), an active quassinoid isolated from Eurycoma longifolia Jack, has been demonstrated to possess anticancer activity. In this study, we aimed to investigate the effect of ECL on sensitizing NSCLC cells to X-radiation (X-ray) as well as the underlying mechanisms. The… More >

ZiJun Liao^*†, Qi Zheng^†, Ting Wei^‡, YanBing Zhang^†, JieQun Ma^†, Zheng Zhao^§, HaiFeng Sun^§, KeJun Nan^*

Oncology Research, Vol.28, No.2, pp. 147-159, 2020, DOI:10.3727/096504019X15732109856009

Abstract MicroRNAs (miRNAs) play crucial roles in tumorigenesis and tumor progression. miR-561 has been reported to be downregulated in gastric cancer and affects cancer cell proliferation and metastasis. However, the role and underlying molecular mechanism of miR-561 in human non-small cell lung cancer (NSCLC) remain unknown and need to be further elucidated. In this study, we discovered that miR-561 expression was downregulated in human NSCLC tissues and cell lines. The overexpression of miR-561 inhibited NSCLC cell proliferation and cell cycle G1 /S transition and induced apoptosis. The inhibition of miR-561 facilitated cell proliferation and G1 /S… More >

Jianping Xu, Xiaoyan Liu, Sheng Yang, Yuankai Shi

Oncology Research, Vol.28, No.2, pp. 127-133, 2020, DOI:10.3727/096504019X15707896762251

Abstract Apatinib, an oral small molecular receptor tyrosine kinase inhibitor (TKI) developed first in China, exerts antiangiogenic and antineoplastic function through selectively binding and inhibiting vascular endothelial growth factor receptor 2 (VEGFR-2). In this study, we aimed to explore the efficacy and safety profile of apatinib monotherapy, or combined with chemotherapy or endothelial growth factor receptor (EGFR)-TKI in heavily pretreated non-small cell lung cancer (NSCLC) patients with brain metastases. We performed a retrospective analysis for relapsed NSCLC patients with brain metastases from our institute, who received apatinib (250 mg or 500 mg p.o. qd) monotherapy, or… More >

Xiuhua Weng^*1, Shaohong Luo^*1, Shen Lin^*, Lixian Zhong^†, Meiyue Li^*, Rao Xin^*, Pinfang Huang^*, Xiongwei Xu^*

Oncology Research, Vol.28, No.2, pp. 117-125, 2020, DOI:10.3727/096504019X15707883083132

Abstract To evaluate the cost–utility of pembrolizumab versus chemotherapy as the first-line setting for metastatic nonsmall cell lung cancer (NSCLC) from the US health care system perspective, a Markov model was developed to compare the lifetime cost and effectiveness of pembrolizumab versus chemotherapy for untreated metastatic NSCLC, based on the clinical data derived from phase III randomized controlled trial (KEYNOTE- 042; ClinicalTrials.gov; NCT02220894). Weibull distribution was fitted to simulate the parametric survival functions. Drug costs were collected from official websites, and utility values were obtained from published literature. Total costs, quality-adjusted life years (QALYs), and incremental… More >

Stefania Nobili^*, Daniele Lavacchi^†, Gabriele Perrone^*, Giulio Vicini^†, Renato Tassi^‡1, Ida Landini^*, AnnaMaria Grosso^§, Giandomenico Roviello^*¶, Roberto Mazzanti^‡, Carmine Santomaggio^¶2, Enrico Mini^*¶

Oncology Research, Vol.28, No.3, pp. 237-248, 2020, DOI:10.3727/096504019X15755437099308

Abstract The use of vinorelbine as a single agent or in combination regimens in non-small cell lung cancer (NSCLC) is associated with satisfactory clinical activity. However, the role of vinorelbine-based chemotherapy in chemonaive locally advanced unresectable or metastatic NSCLC patients, according to real-world treatment patterns, has still not been widely explored. Eighty-one patients treated at a single institution were retrospectively analyzed. Thirty-seven received standard first-line single-agent vinorelbine, and 44 received vinorelbine plus platinum drugs, based on physician’s choice; 61.7% were older than 70 years, and 60.5% were affected by 2 comorbidities. Sixty-three patients were evaluable for… More >

Yanhui Li^*†, Su Dong^*†, Arya Tamaskar^†, Heather Wang^†, Jing Zhao^†, Haichun Ma^*, Yutong Zhao^†

Oncology Research, Vol.28, No.5, pp. 497-507, 2020, DOI:10.3727/096504020X15929939001042

Abstract Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and accounts for 85% of all lung carcinomas. The hepatocyte growth factor receptor (c-Met) has been considered as a potential therapeutic target for NSCLC. Proteasome inhibition induces cell apoptosis and has been used as a novel therapeutic approach for treating diseases including NSCLC; however, the effects of different proteasome inhibitors on NSCLC have not been fully investigated. The aim of this study is to determine a precise strategy for treating NSCLC by targeting c-Met using different proteasome inhibitors. Three proteasome inhibitors, bortezomib,… More >